clonidine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 7 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD)." | 9.14 | The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. ( Fu, Y; Song, C; Wan, Q; Zeng, Y; Zhang, K, 2010) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD)." | 5.14 | The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. ( Fu, Y; Song, C; Wan, Q; Zeng, Y; Zhang, K, 2010) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| " Chronic administration of low doses of the neurotoxin 1-methy,4-phenyl,1,2,3,6-tetrahydropyridine (MPTP) can induce cognitive dysfunction in non-human primates, including impaired performance on a variable delayed response (VDR) task with attentional and memory components." | 1.36 | Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism. ( Decamp, E; Schneider, JS; Tinker, JP, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostock, CY | 1 |
| Hallmark, J | 1 |
| Palumbo, N | 1 |
| Bhide, N | 1 |
| Conti, M | 1 |
| George, JA | 1 |
| Bishop, C | 1 |
| Tanabe, M | 1 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Schneider, JS | 1 |
| Tinker, JP | 1 |
| Decamp, E | 1 |
| Zhang, K | 1 |
| Zeng, Y | 1 |
| Song, C | 1 |
| Fu, Y | 1 |
| Wan, Q | 1 |
| de Rooij, SE | 1 |
| Jansen, PA | 1 |
| Samson, MM | 1 |
| Verhaar, HJ | 1 |
| Moons, CG | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Nash, JR | 1 |
| Wilson, SJ | 1 |
| Potokar, JP | 1 |
| Nutt, DJ | 1 |
1 trial available for clonidine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
Topics: Aged; Arginine; Clonidine; Diagnosis, Differential; Drug Combinations; Female; Human Growth Hormone; | 2010 |
6 other studies available for clonidine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinso | 2015 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Attention; Clonidine; Cognition Disorders; | 2010 |
Growth-hormone release to clonidine and the clinical response to levodopa in parkinsonism.
Topics: Aged; Antiparkinson Agents; Benserazide; Clonidine; Female; Growth Hormone; Humans; Levodopa; Male; | 2002 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I | 2003 |
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drug Administration Schedule; Hu | 2003 |